SNDX (Syndax Pharmaceuticals) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to 2016. Start your Free Trial

What is Syndax Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Syndax Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2025 was 0.00.

Syndax Pharmaceuticals's long-term debt to total assets ratio increased from Mar. 2024 (0.00) to Mar. 2025 (0.00). It may suggest that Syndax Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Syndax Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Syndax Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals LT-Debt-to-Total-Asset Chart

Syndax Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.06

0.05

0.46

Syndax Pharmaceuticals Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	0.46	-

Syndax Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Syndax Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (A: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2024 )	/	Total Assets (A: Dec. 2024 )
	=	333.143	/	724.816
	=	0.46

Syndax Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

LT Debt to Total Assets (Q: Mar. 2025 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2025 )	/	Total Assets (Q: Mar. 2025 )
	=	1.453	/	640.707
	=	0.00

Syndax Pharmaceuticals (NAS:SNDX) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Syndax Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Syndax Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (NAS:SNDX) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

1T3:Germany

Address

730 Third Avenue, 9th Floor, New York, NY, USA, 10017

Website

https://www.syndax.com

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Executives

Keith Katkin	director	C/O UROVANT SCIENCES, INC., 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617
Huber Martin H. Jr.	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Michael A Metzger	officer: President and COO	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD,, WALTHAM MA 02451
Neil Gallagher	officer: President, Head of R&D	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Keith A. Goldan	officer: Chief Financial Officer	227 WASHINGTON STREET, SUITE 200, CONSHOHOCKEN PA 19428
Briggs Morrison	director, officer: Chief Executive Officer	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
William Meury	director	C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Peter Ordentlich	officer: Chief Technology Officer	C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Pierre Legault	director	P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Steve M Sabus	officer: Chief Commercial Officer	10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Dennis Podlesak	director	C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Catherine Madigan	officer: Chief Medical Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Alexander Nolte	officer: Chief Accounting Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Fabrice Egros	director	C/O SYNDAX PHARMACEUTICALS, INC., TOTTEN POND ROAD, SUITE 140, WALTHAM MA 02451
Daphne Karydas	officer: Chief Financial Officer	35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451